Table 3.

Differential antidepressant efficacy and tolerability by group

Variable	Remission rate	Intolerability rate	Proportion taking sick leave	Average sick days
Genetically guided dosing	72% RR=2.52 (95% CI=1.71–3.73, z=4.660, p<0.0001) NNG=3 (95% CI=1.7–3.5)	4%	4%	4.3 (p=0.014)
Genetically unguided dosing	28%	15% RR=1.13 (95% CI=1.01–1.25, z=2.208, p=0.0272) NNG=10 (95% CI=5.0–64.8)	15% RR=1.13 (95% CI=1.01–1.25, z=2.208, p=0.0272)	7.7

The genetically guided group had significantly greater remission rates, better tolerability, and fewer sick days from work. Those subjects treated with genetically guided dosing had a 2.52-fold greater chance of remission form MDD (HDRS ≤ 7) and a 1.13-fold reduced risk of medication intolerability (dose reduction or cessation needed).

RR, risk ratio; NNG, number needed to genotype; HDRS, 17-item Hamilton Depression Rating Scale; MDD, major depressive disorder.